Just five months after raising a $70 million series A round, newly launched Excellergy Inc. agreed to a $2 billion M&A transaction that would bring its trifunctional allergic effector cell response inhibitors (ECRIs) to Novartis AG.
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). At the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), scientists focused on TREM2, a microglial receptor that regulates immune responses, exploring new ways to address neuroinflammation.
BioWorld tracked 152 clinical trial readouts across phases I through III in February 2026, up from 144 in January but down from 215 in December. Of those, 20 phase III trials reported positive results, while one failed to meet key endpoints. By phase, February’s updates consisted of 50 from phase I, 46 from phase II and 57 from phase III.
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: 3D Systems, Agilent, Corcept, Deciphera, Deepecho, Denali, Fennec, GC Biopharma, Invivoscribe, Ono, Rhythm, Royal Philips, Soligenix.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Brainsway, Clemann, Eos Senolytix, Hookipa, Lifeward, Lunai, Microbot, Neurolief, Neotrail, Oramed, Pulmatrix.
Clinical updates for biopharma and med tech, including data readouts and publications: Alzamend Neuro, GH Research, Kodiak, Novocure, Rubedo, Spinogenix, Wave Life.
RSS
